Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOMEDE 2.0: ONC201 vs Everolimus in DIPG and DMG
NCT05476939Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Sep 2022
- Primary completion
- Sep 2028
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of dordaviprone in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Progression-free survival at 2 years. Started Sep 2022; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT05476939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476939.